Print Friendly Page

Protocol No. ALTE15N2

Principal Investigator DeSantes, Kenneth

Phase N/A

Age Group Both

Scope National

Sponsor Type National

Title LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

Objective The overall goals of this study are to:
Learn how the treatment for high-risk neuroblastoma affects your long term health
Learn if treatment for high-risk neuroblastoma affects how we learn and remember, solve problems, complete tasks, and function socially, emotionally, and behaviorally

Key Eligibility
  • Patients must have been enrolled on COG Neuroblastoma Biology Study ANBL00B1
  • Patients must be greater than or equal to 5 and less than or equal to 50 years of age at study enrollment
  • Patient must have been diagnosed with high-risk neuroblastoma per ANBL00B1 definition
  • Patient must have been diagnosed on or after January 1, 2000
  • At least 5 years must have elapsed since diagnosis
  • Patients must have been treated for high-risk neuroblastoma
  • Patients must not be currently receiving active anti-neuroblastoma cytotoxic chemotherapy
  • Patients must not have received anti-neuroblastoma cytotoxic chemotherapy within the last two years
  • Patients with current active neuroblastoma relapse are ineligible

  • Applicable Disease Sites Anal; Bladder; Brain/Central Nervous System; Breast; Cervix; Colon and Rectum; Endocrine cancers; Esophagus; Gastrointestinal cancers, other; Genitourinary cancers, other; Head and Neck; Hematologic cancers, other; Ill-Defined Sites; Kidney; Liver; Lung; Melanoma/Skin cancer; Ovary; Pancreas; Prostate; Sarcoma; Stomach; Thyroid; Unknown Sites; Uterus

    Status Open

    Participating Institutions Gundersen Health System; UW Hospital and Clinics